Literatur
- 1
Albain K S, Barlow W E, Shak S. et al .
Prognostic and predictive
vage of te 21-gene recurrence score assay in postmenopausal women
with node-positive, oestrogen-receptor-positive breast cancer on
chemotherapy: a retrospective analysis of a randomised trial.
Lancet Oncol.
2010;
1
55-65
- 2
Bokemeyer C, Bondarenko I, Makhson A. et al .
Fluorouracil, leucovorin, and oxaliplatin
with and without cetuximab in the first-line treatment of metastatic
colorectal cancer.
J Clin Oncol.
2009;
27
663-671
- 3
Dowsett M, Cuzick J, Wale. et
al .
Prediction of risk of distant recurrence using
21-gene recurrence score in node-negative and node-positive postmenopausal
patients with breast cancer treated with with anastrozole or tamoxifen:
a transATAC study.
J Clin Oncol.
2010;
28
1829-1834
- 4 Gesellschaft der epidemiologischen
Krebsregister in Deutschland/Robert Koch Institut .Krebs in Deutschland 2005 – 2006,
Häufigkeiten und Trends. 7. Auflage. 2010
- 5
Göckenjan G, Sitter H, Thomas M. et al .
Prävention, Diagnostik, Therapie
und Nachsorge des Lungenkarzinoms. Interdisziplinäre S3-Leitlinie
der Deutschen Gesellschaft für Pneumologie und Beatmungsmedizin
und der Deutschen Krebsgesellschaft.
Pneumologie.
2010;
64,S2
e1-e164
- 6
Goldhirsch A, Ingle J N, Gelber R D. et al .
Thresholds for therapies:
Highlights of the St. Gallen International Expert Consensus on the Primary
Therapy of Early Breast Cancer.
Ann Oncol.
2009;
20
1319-1329
- 7
Mitsudomi T, Morita S, Yatabe Y. et al .
Gefitinib versus cisplatin plus docetaxel
in patients with non-small-cell lung cancer harboring mutations
of the epidermal growth factor receptor (WJTG3405): an open label,
randomized phase 3 trial.
Lancet Oncol.
2010;
11
121-128
- 8
Mok T S, Wu Y L, Thongprasert S. et al .
Gefitinib or carboplatin – paclitaxel
in pulmonary adenocarcinoma.
N Engl J Med.
2009;
361
947-957
- 9
Van Cutsem E, Köhne C H, Hitre E. et al .
Cetuximab and chemotherapy
as initial treatment for metastatic colorectal cancer.
N
Engl J Med.
2009;
260
1408-1417
Prof. Dr. med. Bernhard Wörmann
Hämatoonkologische Schwerpunktpraxis
Parkallee 41–45
28209 Bremen
Telefon: 0421/32 04 64
eMail: bwoermann@t-online.de
